过去 90 天内没有内部人买入。最近一笔由 Flagship Ventures Fund V General Partner LLC 披露于 2022年9月16日。
Codiak BioSciences, Inc.：高管交易动态
本页追踪Codiak BioSciences, Inc.高管申报的每一笔交易（来源：SEC (Form 4)）。公司属于医疗与制药行业。Codiak BioSciences, Inc.已超过一年没有高管申报，最近一份可追溯到2023年3月30日。
完整历史始于2020年，共计9笔买入、33笔卖出。
如需在同一行业内比较，可查看Dynavox Group AB和EssilorLuxottica的高管买入记录。这些数据整理自监管申报（来源：SEC (Form 4)），仅描述高管的操作，并非投资推荐。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
财务数据
财年 2021财年截至 2021年12月 · cache
- 1,932 股@ US$0.200.2% 占其流量股票SEC:0000950170-23-011029:1
- 1,932 股@ US$0.1660.6% 占其流量股票SEC:0000950170-23-011026:1
- 13,412 股@ US$0.1693100.0% 占其流量股票SEC:0000950170-23-011028:0
- 11,762 股@ US$0.165233.1% 占其流量股票SEC:0000950170-23-011036:0
- 5,373 股@ US$0.16511.8% 占其流量股票SEC:0000950170-23-011026:0
- 7,432 股@ US$0.20016.5% 占其流量股票SEC:0000950170-23-011029:0
- 1,628 股@ US$0.1955100.0% 占其流量股票SEC:0000950170-23-011055:0
- 41,667 股@ US$0.18100.0% 占其流量股票SEC:0000950170-23-011025:0
- 2,283 股@ US$2.21238.0% 占其流量股票SEC:0000899243-23-005694:1
- 2,407 股@ US$0.59222.2% 占其流量股票SEC:0000899243-23-005694:3
- 2,364 股@ US$2.212953.2% 占其流量股票SEC:0000899243-23-005697:1
- 2,570 股@ US$0.592214.8% 占其流量股票SEC:0000899243-23-005697:3
- 1,512 股@ US$2.213562.3% 占其流量股票SEC:0000899243-23-005687:1
- 1,603 股@ US$0.592916.9% 占其流量股票SEC:0000899243-23-005687:3
- 984 股@ US$2.21244.4% 占其流量股票SEC:0000899243-23-005689:1
- 1,274 股@ US$0.59241.5% 占其流量股票SEC:0000899243-23-005689:3
- 7,112 股@ US$2.21352.7% 占其流量股票SEC:0000899243-23-005695:1
- 7,681 股@ US$0.592214.5% 占其流量股票SEC:0000899243-23-005695:3
- 1,308 股@ US$2.21291.6% 占其流量股票SEC:0000899243-23-005696:1
- 1,391 股@ US$0.59220.4% 占其流量股票SEC:0000899243-23-005696:3
- 7,350 股股票SEC:0000899243-23-005694:2
- 7,613 股股票SEC:0000899243-23-005697:2
- 4,856 股股票SEC:0000899243-23-005687:2
- 3,150 股股票SEC:0000899243-23-005689:2
- 22,969 股股票SEC:0000899243-23-005695:2
90 条申报中的 25 条
About Codiak BioSciences, Inc.
Codiak BioSciences, Inc. (ticker: CDAK) is a U.S.-based biopharmaceutical company historically listed on the NASDAQ market in the United States and focused on exosome-based therapeutics. The company was founded in 2015 through the combination of two venture-creation efforts in the exosome field: one led by ARCH Venture Partners with The University of Texas MD Anderson Cancer Center, and another led by Flagship Pioneering. Codiak built its proprietary engEx® platform to engineer, manufacture, and optimize exosomes as therapeutic delivery vehicles. Its headquarters are in Cambridge, Massachusetts, placing it in one of the most concentrated biotech clusters in the country. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1659352/000119312519125303/d702648ds1.htm?utm_source=openai))
From an industry perspective, Codiak was an early-stage, highly specialized healthcare name operating at the intersection of cell biology, drug delivery engineering, and precision medicine. Its core thesis was that exosomes — naturally occurring intercellular messengers — could be transformed into a new class of biologic medicines capable of carrying therapeutic payloads to targeted tissues. That scientific positioning gave the company a differentiated story in a niche part of biotechnology, aimed at diseases with substantial unmet medical need, including hard-to-treat oncology applications and other complex indications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1659352/000119312523079964/d467120dex991.htm?utm_source=openai))
展开全文收起
Codiak’s main business lines were research and development, preclinical and clinical advancement of product candidates, and process development to refine its exosome engineering and manufacturing capabilities. In other words, the company was primarily a platform developer rather than a commercial-stage drug marketer. For equity investors, that matters: the value proposition depended on scientific validation, clinical data generation, manufacturing scalability, and the potential to create strategic value through partnerships or eventual regulatory success. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1659352/000156459021041658/cdak-10q_20210630.htm?utm_source=openai))
In competitive terms, Codiak operated in an emerging and relatively crowded frontier of advanced therapeutics, where the opportunity is large but the execution risk is also high. Its competitive advantage was centered on its engEx® platform, intellectual property assembled from its founding sources, and early positioning in exosome engineering. However, exosome therapeutics remain technically challenging, with key hurdles including payload loading, targeting, manufacturing consistency, and the long path to clinical and regulatory proof-of-concept. That made Codiak a high-risk, high-upside biotechnology story rather than a mature franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1659352/000119312519125303/d702648ds1.htm?utm_source=openai))
Recent public filings and disclosures indicate a history marked by recurring operating losses, capital dependence, and Form 4 insider transaction reporting. In 2023, the company still described itself as a clinical-stage biopharmaceutical company pioneering exosome-based therapeutics, but the more recent SEC trail should be read cautiously given the financial stress often associated with microcap biotech names. For French-speaking investors in Europe, the key takeaway is that CDAK was a U.S. NASDAQ biotechnology company built around an innovative exosome platform, with significant scientific promise but substantial financing and execution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1659352/000119312523079964/d467120dex991.htm?utm_source=openai))
同行业近期入选信号
我们的模型当前为推荐列表排序的买入。
全部推荐
